Healthcare Industry News: Rainbow SET Pulse CO-Oximetry
News Release - January 22, 2010
Landmark Study Shows Masimo SET(R) Pulse Oximetry and Patient SafetyNet(TM) Can Help Hospitals Dramatically Decrease Rescue Events and ICU Transfers, and ICU DaysIRVINE, Calif., Jan. 22 (Healthcare Sales & Marketing Network) -- Dartmouth-Hitchcock Medical Center and Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, jointly announced the peer-reviewed publication of an in-depth, 21-month clinical study on the impact of the Masimo Patient SafetyNet remote monitoring and clinician notification system. The study, featured in the February 2010 issue of Anesthesiology, is the first published report to demonstrate that continuous pulse oximetry monitoring and clinician notification in post-surgical patients on the general floor leads to a "significant drop" in key clinical outcome measures, including 65% fewer rescue events, 48% fewer ICU transfers, and reduced annualized ICU time by 135 days.(1)
In the study, Dr. Andreas Taenzer and a team of clinicians at Dartmouth-Hitchcock Medical Center used Masimo Patient SafetyNet -- which combines the gold-standard performance of Masimo SET pulse oximetry at the point of care with remote monitoring and wireless clinician notification via pager -- in a 36-bed post-surgical orthopedic unit. When comparing data collected for 11 months before and 10 months after implementation Patient SafetyNet in the 36-bed unit -- as well as two other post-operative units with only standard monitoring equipment and protocols in place -- researchers found that Patient SafetyNet-monitored patients experienced approximately 65% fewer rescue events (1.2 vs. 3.4 per 1,000 patient discharges) and 48% fewer ICU transfers (2.9 vs. 5.6 per 1,000 patient days) -- freeing up 135 ICU days per year, while the two comparison units had no change.
"Masimo Patient SafetyNet represents a new approach to detect unrecognized post-operative deterioration -- a significant precursor in morbidity and mortality for in-hospital patients," stated the lead researcher and author of the study, Andreas H. Taenzer, MD, FAAP, Assistant Professor of Anesthesiology and Pediatrics at the Dartmouth Medical School, Dartmouth-Hitchcock Medical Center, in Lebanon, New Hampshire. "Our study results strongly demonstrate that continuous patient surveillance with Masimo Patient SafetyNet can greatly improve outcomes."
In an accompanying editorial about the impact of the study, John P. Abenstein, MSEE, MD, at the Department of Medicine, Mayo Clinic, in Rochester, Minnesota, wrote that the "implications of this study are broad" and its results could "have important implications for hospital wards throughout the country."(2) According to Dr. Abenstein, "The literature and each of our own clinical experiences have examples of physicians on rounds, or nurses coming to check patients who have been dead for hours." He continued, "We believe that Taenzer et al. have shown us a glimpse of the future" and "Not only will such systems allow us to improve the quality of care of our patients, but will also be a key to lowering costs."
Masimo Founder and CEO, Joe Kiani, stated, "This is one of the most important studies ever published on pulse oximetry because it shows that with Masimo SET Pulse Oximetry technology, improving patient safety and reducing the cost of care can go together. There have been other studies that have shown the positive clinical and cost outcome in neonates and infants by using Masimo SET pulse oximetry, but this is the first time with adults. Over 20 years ago, we set out to solve the motion artifact and low perfusion problems of pulse oximetry, which were the bane of pulse oximetry and were thought to be unsolvable at the time. We thought by overcoming the motion artifact problem, we could improve patient outcome and reduce cost of care by taking noninvasive monitoring to new sites and applications. In fact, this became our mission statement. The clinicians at Dartmouth-Hitchcock, with their culture of patient safety, have shown a breakthrough in patient care is not only possible, but can be attained cost effectively. With this groundbreaking study, our vision is that in the near future, hospitals will utilize this important Patient SafetyNet technology to care for all of their patients, the same way airbags have become ubiquitous in cars today."
(1) Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2.
Available online at:
(2) Abenstein, John P.; Narr, Bradly J. "An Ounce of Prevention May Equate to a Pound of Cure: Can Early Detection and Intervention Prevent Adverse Events?" Anesthesiology, February 2010, Vol. 112, Issue 2. Available online at: http://journals.lww.com/anesthesiology/Citation/publishahead/ An_Ounce_of_Prevention_May_Equate_to_a_Pound_of.99693.aspx
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse CO-OximetryTM, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHbTM), oxygen content (SpOCTM), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced Masimo Rainbow SET® Acoustic MonitoringTM, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo's Rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of study results, risks related to our assumptions that Masimo Patient SafetyNet will provide an effective early warning system of a patient's deteriorating physiological condition to enable timely rescue, risks related to our belief that Masimo Rainbow SET Pulse CO-Oximetry measurements and Masimo Desat Index 3D Alarms will provide sufficient sensitivity and specificity to detect physiological abnormalities and potentially life-threatening conditions in real-time for all patients, and risks related to our assumptions regarding the systems' ability to deliver clinical improvement over alternative patient monitoring and assessment methods to increase patient safety and allow for further adoption of the technology, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.